Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 9/20 | 0.61 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.59 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.51 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.51 |
| ▸ | CASP2 | P42575 | 1/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19283425 | 0.94 | FAAH (0.64) | FAAHDNM1FFAR4FFAR1CASP2 | |
| SCHEMBL76373 | 0.89 | DNM1 (0.72) | FAAHDNM1CASP2 | |
| SCHEMBL74483 | 0.89 | DNM1 (0.72) | FAAHDNM1CASP2 | |
| SCHEMBL3005968 | 0.89 | DNM1 (0.72) | FAAHDNM1CASP2 | |
| SCHEMBL74996 | 0.89 | DNM1 (0.72) | FAAHDNM1CASP2 | |
| SCHEMBL6729860 | 0.89 | DNM1 (0.72) | FAAHDNM1CASP2 | |
| SCHEMBL3411287 | 0.89 | DNM1 (0.72) | FAAHDNM1CASP2 | |
| SCHEMBL8398925 | 0.89 | DNM1 (0.72) | FAAHDNM1CASP2 | |
| SCHEMBL10964167 | 0.89 | DNM1 (0.72) | FAAHDNM1CASP2 | |
| SCHEMBL74821 | 0.89 | DNM1 (0.72) | FAAHDNM1CASP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2872480-B1 | LIPASE-STABLE THICKENING AGENT | EVONIK DEGUSSA GMBH (DE) | 2018-09-26 | — | — | EP | disclosed |
| US-9745251-B2 | Lipase-stable thickening agent | EVONIK DEGUSSA GMBH (DE) | 2017-08-29 | — | — | US | disclosed |
| US-20150203443-A1 | LIPASE-STABLE THICKENING AGENT | EVONIK INDUSTRIES AG (DE) | 2015-07-23 | — | — | US | disclosed |
| EP-2872480-A1 | LIPASE-STABLE THICKENING AGENT | Evonik Industries AG (DE) | 2015-05-20 | — | — | EP | disclosed |
| WO-2014009027-A1 | LIPASE-STABLE THICKENING AGENT | EVONIK INDUSTRIES AG (DE) | 2014-01-16 | — | — | WO | disclosed |
| JP-2004026781-A | USE OF HYDROXY FATTY ACID DIALKYLAMINOALYKYLAMIDE AS HAIR TREATING AGENT | NIKKO CHEMICAL CO LTD | 2004-01-29 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150203443-A1 | LIPASE-STABLE THICKENING AGENT | LIPA, PNLIP, LPL | FAAH 117/4885DNM1 3010/4885FFAR4 642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.